Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
The company is focussed on increasing the capacity utilizations while controlling costs
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
EPS for the period at Rs. (7.57)
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)